Aveanna Announces Pricing of Secondary Offering of Common Stock

Rhea-AI Summary

Aveanna Healthcare (NASDAQ: AVAH) announced the pricing of a secondary offering by selling stockholders affiliated with J.H. Whitney Equity Partners VII: 10,000,000 shares priced at $9.00 per share, with underwriters granted a 30-day option to buy up to an additional 1,500,000 shares.

The company will not sell shares or receive proceeds from the Offering. The sale is expected to settle on October 23, 2025, subject to customary closing conditions. A Form S-3 shelf registration (declared effective) and prospectus supplement are available through the SEC EDGAR system.

Positive

• Offering fully priced at $9.00 per share
• Form S-3 registration declared effective with prospectus available
• Settlement date set for October 23, 2025

Negative

• 10,000,000 shares offered by selling stockholders could increase free float
• Underwriter option could raise total to 11,500,000 shares within 30 days
• Company receives no proceeds from the sale

Insights

Capital Markets Analyst

Secondary sale of 10,000,000 shares at $9.00 by selling shareholders; company receives no proceeds.

The transaction shifts up to 10,000,000 shares (with a 30‑day option for an additional 1,500,000) into public hands at a public offering price of $9.00. The net proceeds will accrue to the Selling Stockholders affiliated with J.H. Whitney Equity Partners VII, LLC, while the company will not receive any proceeds; settlement is expected on October 23, 2025.

Primary dependencies and risks include immediate float expansion and near‑term supply pressure from the sale; market reception will determine short‑term price impact. The use of established underwriters (Jefferies, J.P. Morgan, Barclays, RBC and others) supports orderly distribution but does not change that the company’s equity stake structure shifts.

Watch the actual settlement on October 23, 2025, whether the underwriters exercise the additional 1,500,000‑share option within 30 days, and subsequent disclosures about remaining affiliated holder stakes; these items will clarify the magnitude and duration of any market overhang in the coming weeks.

ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today the pricing of the previously announced secondary offering by certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC (the “Selling Stockholders”) of 10,000,000 shares of its common stock at a public offering price of $9.00 per share (the “Offering”). The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of the Company’s common stock. The Selling Stockholders will receive all of the net proceeds from the Offering. The Company is not offering any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of the shares offered by the Selling Stockholders. The Offering is expected to settle on October 23, 2025, subject to customary closing conditions.

Jefferies and J.P. Morgan are acting as joint lead book-running managers for the Offering. Barclays and RBC Capital Markets are acting as book-running managers for the Offering. BMO Capital Markets, BofA Securities, Truist Securities, Deutsche Bank Securities and PNC Capital Markets LLC are acting as bookrunners for the Offering.

A shelf registration statement on Form S-3 (including a prospectus) relating to these securities has been filed with and declared effective by the Securities and Exchange Commission (the “SEC”). Before you invest, you should read the prospectus in that registration statement, including the documents incorporated by reference therein, the accompanying prospectus supplement and other documents the Company has filed or will file with the SEC for more complete information about the Company and this Offering. You may get these documents, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus may also be obtained, when available, by contacting Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at prospectus_department@jefferies.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aveanna Healthcare

Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 38 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization.

Forward-Looking Statements

Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “would,” “predict,” “project,” “potential,” “continue,” “could,” “design,” “guidance,” or the negatives of these terms or variations of them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, the risks and uncertainties set forth under the heading “Risk Factors” in Aveanna’s Annual Report on Form 10-K for its 2024 fiscal year filed with the SEC on March 13, 2025, which is available at www.sec.gov. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this press release do not purport to be predictions of future events or circumstances, and actual results may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact

Matt Buckhalter
Chief Financial Officer
Ir@aveanna.com

FAQ

What did Aveanna (AVAH) announce on October 22, 2025 about a secondary offering?

Selling stockholders priced 10,000,000 shares at $9.00 per share, with a 30-day option for 1,500,000 additional shares.

Will Aveanna (AVAH) receive proceeds from the October 2025 secondary offering?

No. The press release states the Company will not receive any proceeds; net proceeds go to the selling stockholders.

When is the Aveanna (AVAH) secondary offering expected to settle?

The Offering is expected to settle on October 23, 2025, subject to customary closing conditions.

Who are the underwriters for Aveanna's (AVAH) October 2025 offering?

Jefferies and J.P. Morgan are joint lead book-running managers; Barclays, RBC, BMO, BofA, Truist, Deutsche Bank and PNC are also bookrunners.

Where can investors find the Aveanna (AVAH) prospectus for the October 2025 offering?

The prospectus and registration statement are available on the SEC EDGAR website and from Jefferies or J.P. Morgan per the notice.